期刊文献+

RNA干扰在肺癌基因治疗中的应用进展 被引量:1

Application progress of RNA interference in gene therapy of lung cancer
原文传递
导出
摘要 RNA干扰是近几年在基因表达调控领域的重大发现,是一种经济、快捷、高效的抑制基因表达的技术手段。目前在全球,肺癌发病率呈逐年上升趋势,近10余年来已成为癌症死亡原因之首。肺癌的治疗方法中,靶向基因治疗成为研究热点。RNA干扰作为基因治疗的强大工具,可通过有效沉默原癌基因、细胞凋亡相关基因、细胞周期相关基因、生长因子以及耐药基因等,达到抑制肺癌细胞生长、诱导肺癌细胞凋亡、增强其对化疗或放疗的敏感性的目的。RNA干扰已经广泛应用于肺癌的基因治疗,发挥其明显的抗癌作用。 RNA interference is a major discovery in the field of the regulation of gene expression in recent years. It is an economic, fast, and efficient technological means in inhibiting gene expression. The incidence of lung cancer has been increasing year by year all over the world. In the last ten years, it has been the first cause of cancer deaths. In the treatment of lung cancer, the targeted gene therapy has become a research hotspot. As a powerful tool for gene therapy,RNA interference can inhibit cancer cell growth, induce apoptosis in lung cancer cells, and enhance their sensitivity to chemotherapy or radiotherapy by effectively silencing proto-oncogenes, apoptosis related genes, cell cycle-related genes, growth factors, and drug resistance genes. RNA interference has been widely used in gene therapy of lung cancer,and has a significant anticancer effect.
作者 苗彦 陈愉生
出处 《国际呼吸杂志》 2010年第10期619-625,共7页 International Journal of Respiration
基金 基金项目:福建省自然科学基金资助项目(2008J0074)
关键词 RNA干扰 肺癌 基因治疗 应用进展 RNA interference Lung eaneer Gene therapy Application progress
  • 相关文献

参考文献6

二级参考文献56

  • 1沈维干.RNA interference and its current application in mammals[J].Chinese Medical Journal,2004(7):1084-1091. 被引量:20
  • 2Wood RD. Nucleotide excision repair in mammalian cells. J Biol Chem, 1997, 272: 23465-23468.
  • 3Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cispliatin vs. observation in resected non-small-cell lung cancer . N Engl J Med , 2005 , 352 : 2589-2597.
  • 4Mitsuuchi Y, Johnson SW, Selvakumaran M, et al. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIPI/SDI1 induced by cispatin and paclitaxel. Cancer Res, 2000, 60 : 5390- 5394.
  • 5Olanssen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and eisplatin-based adjuvant chemotherapy. N Engl J Med , 2006,355:983-991 .
  • 6Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine . Ann Oncol,2006,17 : 1818-1825.
  • 7Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival 'after cisplatin plus emcitabine chemotherapy in nonsmall cell lung cancer. Clin Cancer Res, 2002,8:2286-2291.
  • 8Granville CA , Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol , 2005 , 32 : 169-176.
  • 9Pavlov N, Badet J. Angiogenin: involvement in angiogenesis and tumour growth. Bull Cancer,2001,88:725-732.
  • 10Hisai H, Kate J, Kobune M, et al. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res,2003 ,9 :4852-4859.

共引文献41

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部